Many chronic wounds show the stimulation of pro-inflammatory cytokines prolonging the inflammatory phase of healing, which results in more proteases being produced. The impact of chronic wounds on patients can be significant and there is increased risk of infection, which further complicates their treatment. There are also cost implications for the NHS to consider. This article details an evaluation of UrgoCell® Start TLC (Urgo Medical), a dressing that incorporates a healing accelerator (nano-oligosaccharide factor).
